MegaBioWood, an affiliate of KEMIMEDI on “Drug Candidate for Alzheimer's disease”. The total amount of the technology transfer contract was for 6 million US dollars, including $500,000 upfront payment and 5.5 million US dollars as a milestone technology payment.
HULUX, As a company founded based on IBS optogenetics technology, it is currently expanding its business area by developing medical devices using immune-activated RNA.
